PharVision Advisers’s Remitly RELY Stock Holding History

PharVision Advisers’s Portfolio RELY Stock Details RELY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,870	Closed	-$259K	–	952
2025 Q3	$259K	Buy	+15,870	New	+$285K	0.15%	310

Other funds holding RELY

Naspers South Africa $253M AUM 25.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LECM

Lead Edge Capital Management New York $408M AUM 4.05% 1-Year Est. Return

PharVision Advisers's RELY Position: Q4 2025 in Review

PharVision Advisers sold out of Remitly (RELY) in Q4 2025, closing a stake of 15,870 shares — an estimated $259K sold.

PharVision Advisers first reported a position in RELY in Q3 2025 and held it in 1 quarter. The position peaked at $259K in Q3 2025. 282 funds tracked by Wall St. Rank hold RELY as of Q4 2025.

PharVision Advisers reported no remaining Remitly position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 15,870 Remitly shares in Q4 2025, an estimated $259K.
PharVision Advisers first reported a position in Remitly in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Remitly position peaked at $259K in Q3 2025.
282 funds tracked by Wall St. Rank held Remitly as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.